Epstein-Barr virus T-cell immunity despite rituximab

British Journal of Haematology

Volumn 136, Issue 4, 2007, Pages 628-632

  Nehring, Angela K ^a   Dua, Ujjwal ^a   Mollee, Peter ^b   Gill, Devinder ^b   Grimmett, Karen ^b   Khanna, Rajiv ^a   Moss, Denis ^a   Gandhi, Maher K ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Epstein Barr virus; Post transplant lymphoproliferative disorders; Rituximab; T cell

Indexed keywords

CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOMEGALOVIRUS; DRUG EFFECT; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; INFECTION RISK; MALE; MEDICAL ASSESSMENT; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33846404470     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06482.x     Document Type: Article

References (12)

1. Algino, K.M., Thomason, R.W., King, D.E., Montiel, M.M. & Craig, F.E. (1996) CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. American Journal of Clinical Pathology, 106, 78-81.
2. + T-cell memory. Nature Reviews. Immunology, 5, 101-111.
3. Gandhi, M.K. & Khanna, R. (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. The Lancet Infectious Diseases, 4, 725-738.
4. + T-cell function in Hodgkin lymphoma patients. Blood, 108, 2280-2289.
5. Gandhi, M.K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P.J., Prince, H.M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J.F. & Khanna, R. (2006b) Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12, 460-464.
6. Kaplan, L.D., Lee, J.Y., Ambinder, R.F., Sparano, J.A., Cesarman, E., Chadburn, A., Levine, A.M. & Scadden, D.T. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106, 1538-1543.
7. Neelapu, S.S., Kwak, L.W., Kobrin, C.B., Reynolds, C.W., Janik, J.E., Dunleavy, K., White, T., Harvey, L., Pennington, R., Stetler-Stevenson, M., Jaffe, E.S., Steinberg, S.M., Gress, R., Hakim, F. & Wilson, W.H. (2005) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine, 11, 986-991.
8. Savoldo, B., Rooney, C.M., Quiros-Tejeira, R.E., Caldwell, Y., Wagner, H.J., Lee, T., Finegold, M.J., Dotti, G., Heslop, H.E. & Goss, J.A. (2005) Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. American Journal of Transplantation, 5, 566-572.
9. Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A. & Introna, M. (2004) Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Human Gene Therapy, 15, 63-76.
10. Shen, H., Whitmire, J.K., Fan, X., Shedlock, D.J., Kaech, S.M. & Ahmed, R. (2003) A specific role for B cells in the generation of CD8 T -cell memory by recombinant Listeria monocytogenes. Journal of Immunology, 170, 1443-1451.
11. + T cells specific for EBV in healthy virus carriers. Journal of Immunology, 162, 1827-1835.
12. Young, L.S. & Rickinson, A.B. (2004) Epstein-Barr virus: 40 years on. Nature Reviews. Cancer, 4, 757-768.